Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.500 Biomarker group BEFREE Identification of MMTV-associated p14 proteins in benign breast tissues confirms prior PCR-based studies that MMTV infection occurs before the development of MMTV positive breast cancer. 29868468 2018
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.500 Biomarker group BEFREE Expression of ANRIL-Polycomb Complexes-CDKN2A/B/ARF Genes in Breast Tumors: Identification of a Two-Gene (EZH2/CBX7) Signature with Independent Prognostic Value. 27102007 2016
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.500 Biomarker group BEFREE We conclude that YB-1 cooperates with p300 to allow BMI1 to over-ride p16(INK4a) -mediated cell cycle arrest enabling self-renewal and the development of aggressive breast tumors. 24648416 2014
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.500 Biomarker group BEFREE In addition, p16(INK4A)-defective fibroblasts accelerated breast tumor xenograft formation and growth rate in mice. 22751126 2013
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.500 Biomarker group BEFREE We showed that the methylation frequencies ranged from 19.6% (p16 ( INK4a )) to 87% (RASSF1A) in primary breast tumors of Tunisian patients. 19657672 2010
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.500 Biomarker group CTD_human RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response. 20948315 2010
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.500 GeneticVariation group LHGDN Frequent deletion and methylation in SH3GL2 and CDKN2A loci are associated with early- and late-onset breast carcinoma. 18239974 2008
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.500 AlteredExpression group LHGDN [Correlation of p16/INK4a gene damages and protein expression in the tumor tissue of sporadic breast cancer]. 18807517 2008
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.500 AlteredExpression group LHGDN TBX3 is overexpressed in breast cancer and represses p14 ARF by interacting with histone deacetylases. 18245468 2008
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.500 GeneticVariation group LHGDN Low prevalence of CDKN2A/ARF mutations among early-onset cancers of breast, pancreas and malignant melanoma in Poland. 18714178 2008
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.500 GeneticVariation group BEFREE Breast tumors in women with the CDKN2A variant were more commonly intraductal cancers (DCIS) with micro-invasion (14.8% vs. 8.5%; P = 0.035). 17061045 2007
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.500 GeneticVariation group LHGDN Breast tumors in women with the CDKN2A variant were more commonly intraductal cancers (DCIS) with micro-invasion (14.8% vs. 8.5%; P = 0.035). 17061045 2007
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.500 Biomarker group BEFREE Expression of ANRIL mainly coclustered with p14/ARF both in physiologic (various normal human tissues) and in pathologic conditions (human breast tumors). 17440112 2007
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.500 AlteredExpression group LHGDN These results demonstrate a causal role of p16(INK4A) disruption in modulating DNA hypermethylation, and identify a dynamic and active process whereby epigenetic modulation of gene expression is activated as an early event in breast tumor progression. 16766534 2006
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.500 Biomarker group LHGDN A common variant of CDKN2A (p16) predisposes to breast cancer. 15879498 2005
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.500 AlteredExpression group LHGDN p53 activation in chronic radiation-treated breast cancer cells: regulation of MDM2/p14ARF. 14729628 2004
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.500 AlteredExpression group LHGDN Overexpression of p16INK4a correlates with high expression of p73 in breast carcinomas. 15450420 2004
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.500 Biomarker group BEFREE Finally, the results indicate that these proteins are often co-altered in primary breast tumours and that p16INK4a and p14ARF had non-independent behaviour, since they were silenced or overexpressed concomitantly with a significant correlation (p < 0.05). 12579530 2003
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.500 Biomarker group LHGDN Recombinant adenovirus-mediated p14(ARF) overexpression sensitizes human breast cancer cells to cisplatin. 12200117 2002
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.500 AlteredExpression group LHGDN [A study on homozygous deletion, hypermethylation, mutation and expression of p16 gene in human breast cancer]. 11869517 1999
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.500 PosttranslationalModification group BEFREE These data suggest that DNA methylation of the p16 gene in some breast tumours could be the result of an active process that generates a discrete methylation pattern and, hence, could ultimately be amenable to therapeutic manipulation. 9888465 1999
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.500 Biomarker group BEFREE Recently, we reported loss of heterozygosity of the region in which p16(INK4a) is located in more than one-half of primary breast tumors. 9816158 1996
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.500 GeneticVariation group BEFREE Our results suggest that the MTS1 gene is not mutated with increased frequency in primary breast tumors, and thus may not play a major role in breast carcinogenesis. 7889533 1995
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.500 Biomarker group HPO